11 completed, 1 not yet recruiting, 1 withdrawn. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 11, Not yet recruiting 1, Withdrawn 1 |
Follow Pituitary ACTH Hypersecretion: new trials by email Literature Review of Pituitary ACTH Hypersecretion trials Research Report on Pituitary ACTH Hypersecretion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Open-label Treatment in Cushing's Syndrome Levoketoconazole - Cushing Syndrome, Cushing Disease | Phase 3 | Completed | Cortendo AB | 51 | 2019-01-07 | 2025-06-19 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
| Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease osilodrostat, osilodrostat Placebo - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 73 | 2016-10-03 | 2021-11-01 |
| Treatment for Endogenous Cushing's Syndrome Levoketoconazole - Endogenous Cushing's Syndrome | Phase 3 | Completed | Cortendo AB | 94 | 2014-08-01 | 2021-04-19 |
| Mifepristone in Children With Refractory Cushing's Disease mifepristone - Cushing's Disease | Phase 3 | Withdrawn | Corcept Therapeutics | 2013-08-01 | 2014-08-04 | |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 150 | 2011-11-04 | 2018-05-22 |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Pasireotide sub-cutaneous - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 104 | 2011-08-16 | 2018-06-19 |
| Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Mifepristone - Cushing's Disease, Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 4 | 2010-11-01 | 2014-03-18 |
| An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome mifepristone - Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 30 | 2009-07-01 | 2014-04-02 |
| A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome mifepristone - Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 50 | 2007-12-01 | 2013-08-22 |
| Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Cabergoline - Cushing's Disease, Corticotroph Adenoma | Phase 3 | Completed | Seth Gordhandas Sunderdas Medical College | 2007-11-01 | 2009-04-29 | |
| Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Pasireotide - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 162 | 2006-12-01 | 2016-03-08 |
Cushing Syndrome (6) · Pituitary Diseases (5) · ACTH Syndrome, Ectopic (4) · Adrenal Cortex Neoplasms (2) · Choristoma (2) · Hirsutism (2) · Pituitary Neoplasms (2) · ACTH-Secreting Pituitary Adenoma (1) · Acromegaly (1) · Adenoma (1) · Diabetes Mellitus, Type 2 (1) · Growth Hormone-Secreting Pituitary Adenoma (1) · Hyperpituitarism (1) · Hypertension (1)
Brain Diseases (13) · Central Nervous System Diseases (13) · Endocrine System Diseases (13) · Hypothalamic Diseases (13) · Nervous System Diseases (13) · Hyperpituitarism (12) · Pituitary Diseases (8) · Neoplasms (7) · Adrenal Gland Diseases (6) · Adrenocortical Hyperfunction (6) · Endocrine Gland Neoplasms (5) · Neoplasms by Site (5) · Paraneoplastic Endocrine Syndromes (4) · Paraneoplastic Syndromes (4) · Adrenal Cortex Diseases (2)
Mifepristone (4) · Corlux (3) · pasireotide (2) · Cabergoline (1) · Osilodrostat (1) · Proton Therapy (1) · Radiotherapy, Intensity-Modulated (1) · relacorilant (1)
Corcept Therapeutics (5) · Novartis Pharmaceuticals (4) · Cortendo AB (2) · Seth Gordhandas Sunderdas Medical College (1) · University College, London (1)
United States (11) · Spain (7) · Poland (6) · Canada (5) · Germany (5) · Israel (5) · Italy (5) · Belgium (4) · Brazil (4) · France (4) · Greece (4) · Netherlands (4) · Turkey (Türkiye) (4) · Bulgaria (3) · China (3)
Andreas Moraitis, MD (1) · Coleman Gross (1) · Coleman Gross, M.D. (1) · Coleman Gross, MD (1) · Fredric Cohen, MD (1) · Fredric J Cohen, MD (1) · Michael Kosmin (1) · Nalini S Shah, DM (1)
PMID 25013998, PMID 26507877, PMID 22397653, PMID 22466348, PMID 23746264, PMID 23970725, PMID 24287689, PMID 25537481, PMID 27405306, PMID 28289402, PMID 29032078, PMID 31379734, PMID 31465533, PMID 31542384, PMID 31804965, PMID 31875276, PMID 32385851, PMID 33216275, PMID 33897615, PMID 35058882, PMID 35325149, PMID 39610378, PMID 41052284, PMID 41730814
2009 (1)